2 completed. 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
Follow FlowOx 2.0: new trials by email Literature Review of FlowOx 2.0 trials Research Report on FlowOx 2.0
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain FlowOx 2.0 - Multiple Sclerosis, Spasticity, Muscle | Not applicable | Completed | Otivio AS | 58 | 2022-11-04 | 2026-10-19 |
| Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain FlowOx 2.0, FlowOx2.0 (Sham) - Multiple Sclerosis, Spasticity, Muscle | Not applicable | Completed | Otivio AS | 56 | 2022-10-04 | 2026-10-19 |
Multiple Sclerosis (2) · Muscle Spasticity (2) · Chronic Pain (1) · Pain (1)
Otivio AS (2)
Norway (1) · Sweden (1)
Kjell-Morten Myhr, MD, PhD (2) · Peter Vestergaard Rasmussen, MD, PhD (2) · Sara Haghighi Mobarhan Smith, MD, PhD (2)